Lavipharm SA
ATHEX:LAVI
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| GR |
L
|
Lavipharm SA
ATHEX:LAVI
|
227.4m EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
976.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
294.6B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.5B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.7B USD |
Loading...
|
Market Distribution
| Min | -15% |
| 30th Percentile | 20.9% |
| Median | 36.6% |
| 70th Percentile | 50.1% |
| Max | 113.8% |
Other Profitability Ratios
Lavipharm SA
Glance View
Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. The company is headquartered in Athina, Attiki. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. The company is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Lavipharm SA is 47.7%, which is above its 3-year median of 45.5%.
Over the last 3 years, Lavipharm SA’s Gross Margin has increased from 38.9% to 47.7%. During this period, it reached a low of 38.9% on Jun 30, 2022 and a high of 47.7% on Jun 30, 2025.
